Who is sponsoring NCT03639324?

NCT03639324 is sponsored by Virginia Commonwealth University.

What drugs are being tested in NCT03639324?

Interventions in NCT03639324: Dose combination 1-1, dose combination 1-2, Dose combination 1-3, dose combination 1-4, Sub-Trial: Dose combination 2-1, Sub-Trial: Dose combination 2-2.

What condition does NCT03639324 study?

NCT03639324 studies Chronic Lymphocytic Leukemia, CLL, Relapsed CLL, Refractory Chronic Lymphocytic Leukemia, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, SLL, Relapsed Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma.

Is NCT03639324 still recruiting?

NCT03639324 is currently withdrawn. Last updated 9 November 2021.

Last reviewed 2021-11-09 · How we verify

NCT03639324: RIVe-CLL/SLL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL

Withdrawn Phase 1 Last updated 9 November 2021

What this trial tests

Phase 1 trial testing Dose combination 1-1 in Chronic Lymphocytic Leukemia. Withdrawn.

Timeline

2 October 2020

Primary endpoint
18 October 2021

18 October 2021

Quick facts

Lead sponsor	Virginia Commonwealth University
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Start date	2 October 2020
Primary completion	18 October 2021
Estimated completion	18 October 2021

Drugs / interventions tested

Dose combination 1-1
dose combination 1-2 — full drug profile →
Dose combination 1-3 — full drug profile →
dose combination 1-4 — full drug profile →
Sub-Trial: Dose combination 2-1 — full drug profile →
Sub-Trial: Dose combination 2-2 — full drug profile →

Conditions studied

Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →
CLL — all drugs for CLL →
Relapsed CLL — all drugs for Relapsed CLL →
Refractory Chronic Lymphocytic Leukemia — all drugs for Refractory Chronic Lymphocytic Leukemia →

Sponsor

Virginia Commonwealth University

Who can join

18 and older, any sex, with Chronic Lymphocytic Leukemia or CLL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the recommended phase 2 dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) following a lead-in period with idelalisib and rituximab

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J, Nie J, Ma X, Wei Y, et al · · 2019 · cited 1142× · PMID 30782187 · DOI 10.1186/s12943-019-0954-x
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Skånland SS, Brown JR. · · 2023 · cited 30× · PMID 35899388 · DOI 10.3324/haematol.2022.281266
PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches.
Caforio M, de Billy E, De Angelis B, Iacovelli S, et al · · 2021 · cited 29× · PMID 34439194 · DOI 10.3390/cancers13164040
Enhancing venetoclax activity in hematological malignancies.
Satta T, Grant S. · · 2020 · cited 9× · PMID 32600066 · DOI 10.1080/13543784.2020.1789588
A Review of PI3K Inhibitors in B-Cell Malignancies.
Cannon L, Academia EC, Glode AE. · · 2019 · cited 3× · PMID 33391855 · DOI 10.6004/jadpro.2019.10.7.7

Verify or expand the search:

Other recruiting trials for Chronic Lymphocytic Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT07288515 — Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus · recruiting
NCT07014917 — Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL · Phase 2 · recruiting

Other Virginia Commonwealth University trials

Trials by the same sponsor.

NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03639324 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
Last refreshed: 9 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03639324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing